The biologic activity of MER-BCG in experimental systems and preliminary clinical studies.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D005770:Gastrointestinal Neoplasms / Q000628:therapy; D006099:Granuloma / Q000209:etiology; D006801:Humans; D007109:Immunity; D007167:Immunotherapy; D007271:Injections, Intradermal; D007951:Leukemia, Myeloid / Q000628:therapy; D008214:Lymphocytes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008545:Melanoma / Q000628:therapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000628:therapy; D009447:Neuroblastoma / Q000628:therapy; D012871:Skin Diseases / Q000209:etiology; D012878:Skin Neoplasms / Q000628:therapy; D014374:Tuberculin Test
D000970:Antineoplastic Agents; D001500:BCG Vaccine